LY3022855 + durvalumab

LY3022855 + durvalumab is an investigational combination therapy for advanced solid tumors. LY3022855 is a recombinant human monoclonal antibody that targets the colony-stimulating factor-1 receptor (CSF-1R), which plays a role in the regulation of tumor-associated macrophages and the tumor microenvironment. Durvalumab is a human monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), thereby enhancing anti-tumor immune responses by blocking PD-L1-mediated immune suppression. The combination aims to modulate both innate and adaptive immunity to improve anti-tumor activity. Clinical studies have evaluated this combination primarily in patients with advanced non-small cell lung cancer (NSCLC) and ovarian cancer who have progressed after standard therapies. The regimen was generally well tolerated but showed limited clinical activity in early-phase trials[1][2][3][4].